Valette

Valo Health is a technology company using human-centric data and artificial intelligence to transform the drug discovery and development process. The company's proprietary Opal Computational Platform integrates human data across the entire drug development lifecycle, aiming to reduce the time, cost, and failure rate of bringing new medicines to market. Valo focuses on high-impact therapeutic areas including cardiovascular, metabolic, and neurodegenerative diseases, as well as oncology. By leveraging a closed-loop system of data and machine learning, the company identifies novel targets and develops small molecule candidates with a higher probability of clinical success.